Chicago Capital LLC Sells 83,763 Shares of Edwards Lifesciences Co. (NYSE:EW)

Chicago Capital LLC cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 82.0% during the fourth quarter, HoldingsChannel reports. The firm owned 18,408 shares of the medical research company’s stock after selling 83,763 shares during the period. Chicago Capital LLC’s holdings in Edwards Lifesciences were worth $1,363,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of EW. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC increased its position in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. JFS Wealth Advisors LLC increased its holdings in shares of Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares in the last quarter. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $71.46 on Tuesday. The company has a 50 day moving average of $72.49 and a 200-day moving average of $69.73. The company has a market cap of $42.15 billion, a PE ratio of 10.31, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,000 shares of company stock valued at $547,430. 1.27% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

EW has been the topic of a number of recent research reports. Royal Bank of Canada raised their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. The Goldman Sachs Group lifted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research report on Thursday, December 5th. Finally, Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.